For the quarter ending 2025-09-30, BIXT made $760,801 in revenue. -$282,726 in net income. Net profit margin of -37.16%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | - | 102,500 | ||
| General and administrative | 159,131 | 99,531 | ||
| General and administrative affiliates | 336,874 | 22,048 | ||
| Total operating expenses | 496,005 | 224,079 | ||
| Loss from operations | -496,005 | -224,079 | ||
| Change in fair value (fv) of derivative | 264,796 | 307,402 | ||
| Interest expense | 36,522 | 30,112 | ||
| Interest expense affiliates | 10,759 | 15,265 | ||
| Gain/loss of issuance | - | 0 | ||
| Debt discount amortization and issuance of warrants | - | 0 | ||
| Amortization of ip | 4,236 | 2,509 | ||
| Total other income (expenses) | 213,279 | 259,516 | ||
| Net loss before provision for income taxes | -282,726 | 35,437 | ||
| Provision for income taxes | - | 0 | ||
| Net loss | -282,726 | 35,437 | ||
| Net loss attributable to the non-controlling interest | - | 0 | ||
| Net loss attributable to bioxytran | -282,726 | 35,437 | ||
| Earning per common share, basic | 0 | 0 | ||
| Earning per common share, diluted | 0 | 0 | ||
| Weighted average number of common shares out-standing, basic | 88,992,242 | 88,839,723 | ||
| Weighted average number of common shares out-standing, diluted | 88,992,242 | 88,839,723 | ||
BIOXYTRAN, INC (BIXT)
BIOXYTRAN, INC (BIXT)